Surrozen Inc (SRZN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Surrozen Inc (SRZN) has a cash flow conversion efficiency ratio of 0.045x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.49 Million) by net assets ($-278.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Surrozen Inc net asset quality index to measure how much of total assets are equity-financed.
Surrozen Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Surrozen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Surrozen Inc to evaluate the quality of earnings relative to operating cash generation.
Surrozen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Surrozen Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Skymoons Technology Inc.
KQ:033790
|
0.112x |
|
China Steel Structure Co Ltd
TW:2013
|
0.198x |
|
Springsnow Food Group Co Ltd
SHG:605567
|
0.062x |
|
Jackson Acquisition Company II
NYSE:JACS
|
-0.001x |
|
Batavia Prosperindo Int
JK:BPII
|
0.016x |
|
Saha-Union Public Company Limited
BK:SUC
|
0.010x |
|
Pure Cycle Corporation
NASDAQ:PCYO
|
-0.028x |
|
Millenium Hotels Real Estate I SOCIMI S.A.
MC:YMHRE
|
-0.005x |
Annual Cash Flow Conversion Efficiency for Surrozen Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Surrozen Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see Surrozen Inc (SRZN) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-187.76 Million | $-30.24 Million | 0.161x | -80.46% |
| 2024-12-31 | $-21.38 Million | $-17.63 Million | 0.825x | +177.49% |
| 2023-12-31 | $37.94 Million | $-40.36 Million | -1.064x | -83.18% |
| 2022-12-31 | $76.00 Million | $-44.15 Million | -0.581x | -30.54% |
| 2021-12-31 | $109.70 Million | $-48.81 Million | -0.445x | +27.68% |
| 2020-12-31 | $47.29 Million | $-29.10 Million | -0.615x | +14.13% |
| 2019-12-31 | $29.39 Million | $-21.06 Million | -0.717x | -- |
About Surrozen Inc
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, … Read more